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Introduction
In South Africa, prevention of mother-to-child transmission (PMTCT) programmes have been 
very successful in reducing the vertical transmission of HIV, with resultant gains in maternal, 
infant and child health and survival.1,2
Complete elimination of mother-to-child transmission (MTCT) remains elusive, primarily 
because of incomplete programme uptake – owing to suboptimal patient care-seeking behaviour 
and inadequate health care access – but also because no current antiretroviral therapy (ART) 
regimen, even when started early in pregnancy, is 100% effective in preventing transmission. 
Maternal treatment failure resulting from inadequate adherence or drug resistance may also 
compromise PMTCT programme efficacy. In high-prevalence populations and serodiscordant 
partners, primary HIV infection in pregnancy (and breastfeeding), after initial negative HIV 
screening, may contribute disproportionately to transmission.3 Delayed ART initiation and 
apparent incident infection may also be a consequence of false-negative initial testing, owing 
to procedural and quality issues with rapid antibody screening tests. Finally, resistance to non-
nucleoside reverse transcriptase inhibitors (NNRTIs) may compromise the efficacy of infant post-
exposure nevirapine (NVP) ‘mono-prophylaxis’.
Although further gains are possible by improving programme coverage and uptake (and this 
should be encouraged), high-risk vertical exposures at birth remain common and are responsible 
for a high proportion of transmissions. Recognition of increased-risk scenarios, enhanced labour 
management (including intra-partum antiretrovirals [ARVs] and caesarean section before labour), 
infant post-exposure combination ARV prophylaxis (cARP) and a more aggressive testing 
schedule may all reduce transmission risk and improve the linkage of HIV-infected infants to 
definitive management. Whilst it is also important for increased risk to be recognised and managed 
in pregnancy and labour, it is beyond the scope of this article to review obstetric management.
In the developing world, as capacity has grown, PMTCT programmes have evolved from 
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Prevention of mother-to-child transmission (PMTCT) programmes have improved maternal 
health outcomes and reduced the incidence of paediatric HIV, resulting in improved child 
health and survival. Nevertheless, high-risk vertical exposures remain common and are 
responsible for a high proportion of transmissions. In the absence of antiretrovirals (ARVs), 
an 8- to 12-hour labour has approximately the same 15% risk of transmission as 18 months 
of mixed feeding. The intensity of transmission risk is highest during labour and delivery; 
however, the brevity of this intra-partum period lends itself to post-exposure interventions to 
reduce such risk. There is good evidence that infant post-exposure prophylaxis (PEP) reduces 
intra-partum transmission even in the absence of maternal prophylaxis. Recent reports suggest 
that infant combination ARV prophylaxis (cARP) is more efficient at reducing intra-partum 
transmission than a single agent in situations of minimal pre-labour prophylaxis. Guidelines 
from the developed world have incorporated infant cARP for increased-risk scenarios. In 
contrast, recent guidelines for low-resource settings have rightfully focused on reducing 
postnatal transmission to preserve the benefits of breastfeeding, but have largely ignored the 
potential of augmented infant PEP for reducing intra-partum transmissions. Minimal pre-
labour prophylaxis, poor adherence in the month prior to delivery, elevated maternal viral 
load at delivery, spontaneous preterm labour with prolonged rupture of membranes and 
chorioamnionitis are simple clinical criteria that identify increased intra-partum transmission 
risk. In these increased-risk scenarios, transmission frequency may be halved by combining 
nevirapine and zidovudine as a form of boosted infant PEP. This strategy may be important to 
reduce intra-partum transmissions when PMTCT is suboptimal.
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through targeted maternal combination ART (cART), to 
the universal, lifelong ‘treatment-as-prophylaxis’ defined 
by the 2013 World Health Organization (WHO) guidelines. 
Each step in this evolution has resulted in progressive 
reductions in vertical transmission and improvements in 
maternal care. Infant prophylaxis has grown from post-
exposure prophylaxis (PEP) for intra-partum risk to include 
post-partum peri-exposure prophylaxis (PEEP) intended to 
render breastfeeding safer. In the developing world, with the 
focus on reducing transmission during breastfeeding, little 
consideration has been given to quantification of the intra-
partum risk or to boosting infant PEP for increased intra-
partum risk scenarios.
In contrast, developed-world PMTCT guidelines routinely 
quantify intra-partum risk and recommend boosted 
infant PEP for increased-risk scenarios. In the event of no 
or minimal pre-labour prophylaxis, National Institutes 
of Health guidelines recommend the addition of 3 doses of 
infant NVP in the first week of life to the standard 6 weeks 
of infant zidovudine (AZT).4 British HIV Association 
(BHIVA) guidelines recommend triple ARV prophylaxis for 
infants when the maternal viral load (VL) is > 50 copies/mL, 
and only recommend AZT mono-therapy if the maternal 
VL is fully suppressed from 36 weeks’ gestation.5 Both 
guidelines acknowledge a growing body of expert opinion 
that the benefits of infant post-exposure cARP exceed its risks 
when transmission risk is increased.
Ironically, pre-2010 South African guidelines provided 
for routine infant dual prophylaxis with single-dose NVP 
(sdNVP) and one week of AZT, and infants whose mothers 
had less than 4 weeks of pre-labour prophylaxis were assigned 
to sdNVP and 4 weeks of AZT.6 This policy incorporated 
an element of risk recognition and response and was based 
on findings of the ‘Thai long-short, short-long’ and NVAZ 
studies.7,8
Quantifying risk
cART initiated early in pregnancy, with a resultant 
suppressed VL, and avoidance of breastfeeding virtually 
eliminate vertical transmission. However, even in the 
developed world, transmissions occur because of suboptimal 
antenatal care, failure of maternal and infant prophylaxis 
and primary HIV infection in pregnancy. These factors argue 
for an augmented approach to infant management in such 
increased-risk settings. Consequently, guidelines emanating 
from the developed world have incorporated elements of 
risk assessment and response.
In the absence of ARVs, HIV transmission rates are 
approximately 5% – 10% during pregnancy, 10% – 20% 
during the intra-partum period, and 10% – 20% during 
extended mixed breastfeeding.9 Whilst transmission is 
minimal in early pregnancy, the frequency of infection 
increases significantly in the third trimester towards term, 
and peaks at 10% – 20% during the 8–12 hours of labour and 
delivery, making the latter the most intense risk period.10 
The intensity of risk is very low throughout breastfeeding, 
but the cumulative risk over time may be high. Factors 
strongly associated with increased transmission risk are: 
high maternal VL, low maternal CD4 count, the absence of 
maternal ART, and preterm labour with prolonged rupture 
of membranes.11 Whilst the first three factors are associated 
with increased transmission in all risk periods, preterm 
labour, especially with prolonged rupture of membranes, 
appears only to increase intra-partum transmission risk.
The Women and Infant Transmission Study (WITS) found 
intra-partum transmission to be associated significantly with 
a lack of ART, an increased VL, a low CD4 percentage, young 
gestational age, low birth weight (LBW), prolonged rupture 
of membranes and hard drug use. Overall transmission, 
particularly the intra-partum proportion, has declined 
significantly over time, reflecting the success of peri-partum 
maternal interventions and infant PEP.12 Consequently, 
the proportion of in utero transmissions is higher. In South 
Africa, the proportion owing to transmission during 
breastfeeding remains uncertain, as the uptake and duration 
of breastfeeding are unknown, and long-term follow-up to 
ascertain postnatal transmission rates has been difficult to 
achieve.
Intensity of risk varies during pregnancy and breastfeeding 
according to the timing of ART initiation, the duration 
of ART and the impact on VL by the time of delivery 
and breastfeeding. For example, a woman who is newly 
diagnosed immediately after delivery will be at high risk 
for transmission in the antenatal and intra-partum periods 
and will have some risk during early breastfeeding until 
maternal cART takes effect. In this scenario, infant ARV 
prophylaxis is critical for reducing transmission during 
labour and delivery, and exclusive breastfeeding, maternal 
cART and infant PEEP are vital for risk reduction in the first 3 
months of breastfeeding. Heat-treatment of breast milk until 
an adequate duration of maternal cART or viral suppression 
has been achieved is an option to eliminate breastfeeding 
transmission risk entirely. This is especially important to 
preserve breastfeeding as an option for preterm/LBW infants 
who are more likely to experience serious adverse events in 
the first 6 months of life if replacement fed, even if not HIV 
exposed.13
In contrast, a woman who initiates ART from 34 weeks’ 
gestation, has good adherence, is virally suppressed and 
delivers at 40 weeks’ gestation will have some risk of 
transmission during pregnancy, but very little risk during 
labour and breastfeeding. Whilst a polymerase chain 
reaction (PCR) test at birth is indicated to detect pre-labour 
transmissions, infant cARP does not add much benefit and 
there is no real benefit in extending PEP beyond 6 weeks. It 
would be wrong to recommend replacement feeding in this 
case, unless the conditions for safe formula feeding were met.
It is difficult to incorporate this degree of risk assessment 
nuance into PMTCT programmes, and it may be better to 
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have a binary approach where any non-low-risk scenario, 
irrespective of risk period, attracts an enhanced response 
for intra-partum management, infant testing and cARP. 
The introduction of universal PCR testing at birth would 
simplify the issue and allow the focus to be solely on flagging 
increased intra-partum risk exposures for infant cARP. The 
definition of ’non-low risk’ and extent of the response will 
need to be balanced against its cost and available resources. 
If this approach is adopted, then it is important to guard 
against the perception that all non-low-risk infants should 
avoid breastfeeding. Many infants in this category are at 
particularly high risk of formula-feeding-related morbidity 
and mortality; therefore, exclusive breastfeeding should be 
encouraged unless the criteria for safe replacement feeding 
are met.
The community living with HIV has had significant exposure 
to NNRTIs as part of first-line treatment and as single doses 
administered during labour. NNRTI resistance develops 
rapidly after limited exposure, requiring only a single base 
pair mutation, and vertical transmission of resistant virus 
has been described.14,15 Primary and acquired resistance is not 
uncommon and, when NNRTI resistance is likely, it seems 
unwise to rely on NVP mono-therapy for infant PEP when 
intra-partum risk is increased, even if the mechanism of 
prophylaxis is different to that of treatment. In contrast, AZT 
resistance requires numerous mutations and takes longer 
to develop. Therefore, AZT is important to enhance infant 
PEP in order to reduce intra-partum transmission risk when 
maternal virus is likely to be NNRTI resistant.
NNRTI resistance is likely in women who are failing, or have 
failed, first-line ART, or are on second- or third-line regimens. 
In such circumstances, it seems logical, at least, to combine 
infant NVP with AZT if the maternal VL is not suppressed 
by delivery. The 2013 South African Paediatric Standard 
Treatment Guidelines recommend expert consultation if 
resistance is possible, but do not provide advice on reducing 
the peak risk during labour and delivery with boosted infant 
PEP.16
The following factors are likely to increase vertical 
transmission risk:
Maternal factors
• duration of maternal ART < 8 weeks (especially if no pre-
labour ART)
• maternal VL > 1000 copies/mL close to term (not always 
available)
• maternal viral rebound (treatment interruption, poor 
adherence, true resistance)
• maternal co-morbidity (TB, opportunistic infections, 
chorioamnionitis)
• incident infection (initial HIV test negative, subsequently 
tests positive)
• likely NNRTI resistance (second-line ART, failing first-
line ART; several sdNVP previously)
• adolescent pregnancy (recent/incident/vertically trans-
mitted infection, more likely to have problems with 
follow-up)
• maternal substance abuse (alcohol or drugs).
Infant factors
• symptomatic (severe growth restriction, lympha denopathy, 
hepatosplenomegaly, thrombocytopaenia, pancytopaenia, 
congenital cytomegalovirus, congenital syphilis, neonatal 
tuberculosis)
• preterm delivery (regardless of cause) and/or LBW 
infants (< 2500 g; < 37 weeks‘ gestation)
• abandoned infants (if Alere Determine or  enzyme-linked 
immunosorbent assay [ELISA] positive).
PCR testing soon after birth will identify infants infected 
in utero, facilitate linkage to definitive care and, hopefully, 
reduce early mortality. Those not infected in utero will, in many 
instances, also have an increased intra-partum transmission 
risk and may benefit from enhanced infant PEP. In contrast 
to the peak risk intensity in labour and delivery, transmission 
risk intensity per breastfeeding session is extremely low but, 
owing to a relatively high cumulative risk over time, tends 
to be overstated. Therefore, the need for enhanced infant 
PEEP for breast milk exposure is less urgent than PEP for 
high-risk intra-partum exposure, and the cornerstone of risk 
reduction in this period remains the urgent optimisation of 
maternal cART. There is currently no evidence that infant 
cARP reduces breastfeeding transmission.
Post-exposure prophylaxis reduces  
transmission risk
ARV PEP, soon after HIV exposure in various settings, is well 
established as routine management to prevent transmission:
• In 1997 a case-control study reported that post-exposure AZT 
mono-prophylaxis reduces transmission in occupational 
exposures.17 Since then, post-exposure cARP has become 
the standard of care for occupational exposures. Without 
prophylaxis, the risk of HIV infection from a penetrating 
injury with an HIV-contaminated needle is estimated at 
0.3% compared with an estimated 15% vertical transmission 
risk in labour.
• Post-exposure cARP is established as the standard of care 
after sexual assault and after inadvertent exposure of an 
infant to another mother’s HIV-infected breast milk.
• According to Wade et al. in 1998, when AZT was started 
before 48 hours of life for PMTCT, transmission was 9.3% 
(4.1% – 17.5%) and, when started on day 3 of life or later, 
it was 18.4%. Transmission was 26.6% (21.1% – 32.7%) in 
the absence of AZT.18
• A study of HIV-exposed, formula-fed infants whose 
mothers received no prophylaxis before delivery reported 
that infant sdNVP or 6 weeks of AZT were equally efficient 
at reducing vertical transmission. At 6 weeks, transmission 
was 5.3% with sdNVP and 6.4% with AZT – both 
considerably less than anticipated without prophylaxis.19
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Infant prophylaxis probably contributes little to reducing 
transmission risk when maternal cART is started early and 
viral suppression is optimal by the last weeks of pregnancy. 
Extended or augmented infant PEP cannot compensate for 
suboptimal antenatal prophylaxis, and early maternal ART 
with VL suppression remains critical to prevent transmission 
at all times.
Ideally, patients with an increased risk of intra-partum 
transmission should be flagged for possible elective caesarean 
section to avoid intra-partum exposure. When maternal 
prophylaxis is suboptimal, the intra-partum risk peak is a 
critical opportunity for intervention and, importantly, its 
relative brevity makes it amenable to infant PEP. In non-
breastfeeding settings, infant PEP targets intra-partum 
risk alone and is the key intervention for reducing intra-
partum transmission when there has been no pre-delivery 
prophylaxis. In breastfeeding settings, infant cARP must 
include an ARV that reduces breast milk transmission risk 
(PEEP) as well. Infant AZT treatment has not been shown 
to be effective in this regard. PEP is usually only effective 
if initiated within 48–72 hours of delivery. Infant PEP is not 
effective in reducing in utero transmission, but should be 
commenced as soon as possible after birth to reduce intra-
partum transmission.
In most situations, PEP duration is typically 4 weeks but, in 
the context of PMTCT, AZT for 6 weeks was established as 
standard by the PACTG 076 study.20 In non-breastfeeding 
settings, there is no real evidence that AZT PEP for 6 
weeks is superior to 4 weeks, and the shorter option may 
be associated with a lower incidence of anaemia and 
neutropaenia. Pundits for the longer course cite slow decay 
of transferred intracellular maternal virus as a reason for 
extending infant PEP.
Post-exposure combination 
antiretroviral therapy reduces 
transmission risk in increased-risk 
situations
Outside of PMTCT settings, exposures of considerably lower 
risk (occupational, sexual assault and inadvertent breastmilk 
exposures) routinely attract cARP. Whilst infant cARP for 
increased-risk MTCT scenarios is routine in the developed 
world, little consideration has been given to boosting infant 
PEP to prevent vertical transmission in the developing world.
If viral suppression by the onset of labour is suboptimal, 
the risk of intra-partum transmission is increased, and the 
relatively short duration of labour and delivery makes infant 
cARP an option for reducing transmissions.
Whilst data to support this approach are limited, there is 
some direct evidence that infant cARP is more effective than 
a single agent:
• In infants where maternal pre-labour ARVs were absent 
or minimal, the addition of 3 doses of infant NVP to 
the standard 6 weeks of AZT reduced intra-partum 
transmission from 4.8% (confidence interval [CI] = 3.2–
7.1) to 2.2% (CI = 1.2–3.9; p = 0.046).21
• A study in Malawi by Taha et al. reported that the 
addition of 1 week of AZT to sdNVP reduced intra-
partum transmission from 12.1% to 7.7% (p = 0.03).22
Post-exposure combination 
antiretroviral therapy options and 
recommendation for South Africa
There are two main potential benefits of cARP:
• reduced intra-partum transmission
• prophylaxis as very early treatment of HIV-infected 
infants while awaiting PCR results.
A potential disadvantage is consequent difficulty in 
confirming infection owing to the effect on VL, but this 
is already an issue with extended NVP mono-therapy in 
infants. A higher rate of anaemia owing to extended infant 
AZT argues for restricting the AZT component to 4 weeks.
Selection of appropriate ARVs for combination prophylaxis 
is problematic as there are limited pharmacokinetic, safety 
and efficacy data for the use of many agents in the neonatal 
period, and more so in combination and with preterm 
babies. Whilst the imperative of early treatment justifies the 
use of some of these agents in neonatal cART for newborns 
infected in utero, it is more difficult to justify their use as 
cARP in HIV-exposed neonates who, for the most part, 
remain uninfected.
The 2008 South African PMTCT programme recommended 
sdNVP and AZT extended to 1 or 4 weeks. Since 2010, 
extended infant daily NVP up to 12 months has been used as 
PEP and breastfeeding prophylaxis.
AZT, lamivudine (3TC) and NVP as infant prophylaxis 
are the most used and studied agents globally. There are 
good study data on the safety and efficacy of these agents 
as part of comprehensive PMTCT regimens.23,24,25 BHIVA 
guidelines recommend these three drugs in combination 
for infant PEP when transmission risk is not minimal. If 
drug resistance is likely, consideration needs to be given 
to other agents not usually used for infant PEP, and then 
only under expert guidance and preferably with resistance 
genotyping.26
Lopinavir/ritonavir (LPV/r) has been associated with very 
significant toxicity and is not recommended for use before 
42 weeks’ corrected gestational age, limiting its usefulness as 
an option in cARP.27 Where multidrug resistance is identified 
by maternal virus genotyping prior to delivery, serious 
consideration may need to be given to LPV/r use as infant 
cARP, but then only in a strictly controlled environment.
As extended infant NVP facilitates safer breastfeeding by 
HIV-infected infants, it makes sense to retain NVP as the 
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core of infant prophylaxis and add 4 or 6 weeks of AZT 
and possibly 3TC. There is no evidence that extending AZT 
or 3TC beyond 6 weeks confers any further intra-partum 
transmission reduction, or that it affects breastfeeding risk. 
Both LPV/r and 3TC as single agents extended to 12 months 
of breastfeeding have recently been reported in the PROMISE 
PEP study to reduce HIV transmission during breastfeeding 
to very low levels.28
Currently, in South Africa, the two main options for cARP 
are for a two- (AZT, NVP) or three-drug (AZT, 3TC, NVP) 
approach. There is little evidence to support one over the 
other and, indeed, the three-drug approach in HPTN040 
showed no clear benefit over the two-drug approach.
Dosage tables for NVP (Table 1) and AZT (Table 2) are given 
below. These tables are modified from the Western Cape 2014 
PMTCT Guidelines, include doses for preterm infants, and 
differ slightly from doses provided in the current National 
Guidelines.
The recommended dosage for 3TC is 2 mg/kg for the first 
4 weeks of life, irrespective of gestational age at birth.
Conclusion
The most intense period of risk for MTCT is during labour 
and delivery. This is accentuated by suboptimal maternal 
viral suppression and limited pre-labour cART duration.
An increased risk of intra-partum HIV infection can be 
reduced by boosted infant PEP. Newborns at increased risk 
can be identified by clinical and laboratory parameters at 
birth, be tested early, and receive post-exposure cARP if the 
birth PCR test is negative.
Risk of transmission during breastfeeding is low but, because 
of the cumulative risk over the whole breastfeeding period, 
tends to be overstated. Breastfeeding risk per month is very low 
with maternal cART and infant PEEP. In high-risk scenarios, 
maternal ART/adherence must be optimised urgently to 
reduce breastfeeding transmission risk and improve maternal 
health and survival. There are no data on the efficacy of cARP 
to prevent breastfeeding transmission of HIV in high-risk 
situations, and the potential toxicity of extended cARP means 
it cannot be recommended for this purpose.
PCR testing at birth is recommended for infants commencing 
cARP and when in utero transmission risk is high, to 
respectively exclude HIV infection and facilitate prompt 
linkage of infected infants to definitive treatment.
Appendix 1 contains commentary on the new South African 
Consolidated guidelines for PMTCT and the management of HIV 
in children, adolescents and adults that were released after the 
writing of this article.
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Appendix 1: Recognising 
and managing increased HIV 
transmission risk in newborns
In January 2015, the South African National Department of Health 
(NDoH) issued the new Consolidated guidelines for PMTCT and 
the management of HIV in children, adolescents and adults. This 
document includes risk criteria linked to more intensive testing 
and prophylaxis regimens.
Immediate PCR testing including birth testing is now recommended 
for many increased risk situations.
Infant post-exposure cARP with AZT and NVP for increased intra-
partum risk is recommended for 6 weeks when the most recent 
maternal VLs are > 1000 copies/mL. If maternal ART duration is < 
4 weeks or the diagnosis of maternal HIV is made during labour or 
after delivery, infant breastfeeding PEEP with NVP as a single agent 
is extended to 12 weeks.
Unfortunately, cARP is not recommended for the very situation 
where evidence for risk reduction is strongest: when there is no 
pre-labour ART and a current VL result is not available. Another 
important omission is the use of cARP for suspected maternal virus 
NNRTI resistance in instances where it does not make sense to rely 
solely on NVP for prevention.
Curiously, maternal seroconversion during breastfeeding does 
attract temporary cARP with AZT for 1 week and extended NVP, but 
this advice seems illogical and the evidence for benefit is lacking.
Unlike the 2013 WHO consolidated guidelines, the NDoH 
guidelines make no mention of ARV prophylaxis dosing for preterm 
and LBW infants. The NVP dosing schedule recommends 20 mg for 
all infants > 6 weeks old. Many preterm infants may weigh < 2 kg 
at 6 weeks, and the 20 mg dose may be too high. Moreover, the 
simplified AZT dosing schedule does not include recommendations 
for infants weighing < 2 kg.
Whilst the consolidated guidelines are a step in the right direction, 
they could be improved further, and clinicians should carefully 
consider whether patients with increased-risk intra-partum HIV 
exposure may benefit from enhanced prophylaxis. The adoption 
of universal birth PCR testing would simplify risk management 
and the selection of infants for cARP. Point-of-care nucleic acid 
testing in delivery facilities has great potential for routine maternal 
VL testing to determine intra-partum transmission risk and to 
facilitate universal birth PCR testing for HIV-exposed newborns.
